Towards improved quality of life in multiple sclerosis
Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and potentially other disorders. Spasticity is a debilitating and painful symptom of MS that consists of involuntary spasms of limbs and torso. The goal of the Canbex lead programme is to set a new standard in the treatment of spasticity, through improved tolerability.
The company’s lead compound, VSN16R, is currently in Phase I human safety trials.
Investors in Canbex include MS Ventures, the corporate venture arm of Merck KGaA; the Wellcome Trust; "Fast Forward", the drug development arm of the US National Multiple Sclerosis Society; University College London (UCL Business PLC); and Esperante Ventures.